在患有ST段升高心肌梗塞的患者中,Cangrelor,Tirofiban和或标准的Prasugrel疗程:FABOLUS- FASTER试验的主要结果
在PubMed上查看摘要
概括
此摘要是机器生成的。在ST升高心肌梗塞患者中,Cangrelor的血小板抑制率低于tirofiban. 与整体普拉苏格雷尔相比,的普拉苏格雷尔没有改善血小板抑制.
科学领域
- 心脏病学
- 药理学
- 干预心脏病学
背景情况
- 标准口服P2Y12抑制剂 (普拉苏格勒,蒂卡格勒) 在接受初级皮肤冠状动脉干预 (PCI) 的ST升高心肌梗塞 (STEMI) 患者中提供低于最佳的早期血小板抑制.
- 研究其他抗血小板策略对于改善STEMI患者的治疗结果至关重要.
- 在FABOLUS- FASTER试验中,通过比较康格洛尔,蒂罗菲班和普拉苏格勒疗程来解决这一问题.
研究的目的
- 在接受初级PCI的STEMI患者中,将康格罗尔和蒂罗菲班的早期血小板抑制与普拉苏格勒进行比较.
- 评估和整体普拉苏格雷尔加重剂量对血小板聚合的疗效.
- 评估不同抗血小板药物对达到适当的血小板抑制的影响.
主要方法
- 一个多中心的,开放的,随机的试验,涉及122名接受初级PCI的P2Y12原始STEMI患者.
- 患者被随机分为接受康格洛尔,蒂罗菲班或普拉苏格勒.
- 普拉苏格勒进一步分类为或整体药片.
- 主要终点是使用光透度聚合计进行30分钟的血小板聚合抑制 (IPA).
主要成果
- 与铁洛非相比,Cangrelor没有达到非劣质性,而铁洛非显著优于IPA (95. 0±8. 9%与34. 1±22. 5%).
- 与的普拉苏格雷尔相比,康格雷罗和蒂罗菲班的IPA都更高 (10. 5± 11. 0%).
- 尽管活性代谢物度更高,但的普拉苏格勒与整体普拉苏格勒相比没有更高的IPA (6. 3±11. 4%).
结论
- 在接受初级PCI的STEMI患者中,Cangrelor的早期血小板抑制效果低于tirofiban.
- 虽然康格洛尔和蒂罗菲班都比的普拉苏格勒更有效,但后者与整体普拉苏格勒相比没有优势.
- 这些研究结果表明,在这种患者群体中,提罗非班可能是早期强烈血小板抑制的首选选择.
相关概念视频
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

